# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹356 Cr** Q4 (+22%) · **₹1,283 Cr** FY26 (+18%) * **Gross Margin:** **7.3%** Q4 · **7.5%** FY26 (+100 bps) * **Working Capital Cycle:** **18 Days** * **Total Treasury:** **₹500 Cr** Group-wide ## B. Revenue Growth * **Strategic Scaling:** Robust annual top-line expansion driven by a focus on operational efficiency, with total revenue successfully crossing the **₹1,300 Cr** milestone. * **Margin Expansion:** Significant gross profit outperformance relative to revenue growth, fueled by an optimized product mix and procurement efficiencies. ## C. Margins & Profitability * **Path to Breakeven:** EBITDA losses narrowed substantially due to disciplined cost management and operational leverage; Health X Platform specifically saw a massive turnaround in annual PAT. * **Investment vs. Returns:** Current losses are primarily attributed to **tech investments and brand-building**; however, core units like Retailer Shakti are now covering corporate costs and are contribution-margin positive. * **Treasury Alpha:** Active management of treasury assets generates **10%-12%** yields (vs. 7%-8% standard), providing an additional **₹20 Cr** annually to offset operational burn. * **Capital Philosophy:** Management prioritizes capital efficiency and share buybacks over "purchasing revenue" through debt or aggressive capital deployment. ## D. Balance Sheet * **Asset-Light Efficiency:** Maintains an industry-leading working capital cycle and high capital efficiency, with total capital employed of approximately **₹74 Cr**. * **Demerger Dynamics:** The establishment of Microsec Resources creates a vehicle for **₹140 Cr** in assets, including **₹40 Cr** in real estate intended for eventual liquidation to capitalize the new entity. * **High-Yield Investments:** Treasury includes unquoted NSE shares acquired at **₹1,600/share**, expected to yield **15%** annualized returns and potentially net **₹95-100 Cr** upon exit. * **Liquidity Position:** Strong cash buffer with **₹30 Cr** in immediate cash/FDs, supplemented by a massive **₹400 Cr** treasury holding within Health X Limited. --- # 2. Business Model & Strategy ## A. Key Figures * **Total Capital Deployed:** **₹259 Cr** Including 9% cost of capital * **Expansion Capex:** **₹234 Cr** Total · **₹134 Cr** Bank loans · **₹100 Cr** Internal treasury ## B. Capital Allocation & Restructuring * **Strategic Demerger:** Approved plan to spin off the Finance Division into **Microsec Resources Ltd.**; shareholders to receive **1 new share for every 3 shares** held. * **Capital Efficiency:** Management maintains a conservative, low-cost experimentation model, prioritizing capital efficiency over the high-burn strategies typical of Indian startups. * **Shareholder Value:** Prioritized non-dilutive growth by executing a **buyback from Mitsubishi Corporation** rather than raising external investor capital. * **Resource Deployment:** The retained treasury is earmarked for the next phase of operational investment and business growth rather than permanent holding. ## C. Strategic Initiatives * **Operational Model:** Focus on a scalable, AI-powered ecosystem for procurement and fulfillment; strictly adheres to a **cash-and-carry** model to avoid capital-intensive hospital credit risks. * **Human Capital:** Shifted to internal payroll to curb attrition and build loyalty; strategy has successfully delivered a **significantly lower attrition rate** versus e-commerce peers. * **Sector Focus:** Remains concentrated on healthcare (Health X and RetailerShakti) due to massive market tailwinds, with further strategic pivots deferred until after the **March 30, 2027** demerger completion. ## D. Vision & M&A * **Ecosystem Evolution:** Transitioned identity in **FY26** from pure healthcare commerce to a comprehensive digital healthcare, diagnostics, and preventive care platform. * **Future Partnerships:** M&A or team-building for the financial arm is secondary to the current year's focus on **AI applications and new warehouse construction**. --- # 3. Product & Segment Performance ## A. Key Figures * **Regional Growth Rates:** **>50%** Northeast · **>25%-30%** Northern India ## B. Product Portfolio * **Strategic Pivot to Private Labels:** Launched **JITO**, a certified generic category priced significantly lower than branded alternatives to capture high-margin healthcare spend. * **Inventory Expansion:** Broadened offerings to include surgical and medical devices; personal and beauty care categories are slated for rollout by **December 31, 2026**. * **Transitionary Headwinds:** The shift to the **Jito Store** model caused temporary friction in branded medicine sales, though a recovery is anticipated by year-end. ## C. Operating Segments * **B2B Platform Dominance:** Retailer Shakti now serves over **62,000 pharmacies**; the segment is operating near breakeven with positive contribution margins across both B2B and B2C verticals. * **JITO Revenue Mix:** The new generic initiative generates **₹30 lakhs** in monthly sales, with the B2B platform contributing double the volume of the B2C channel. * **Geographic Diversification:** Growth in non-core regions (Northeast and North India) is now outstripping the home market, with active penetration strategies targeting **Lucknow**. * **Legacy Assets:** Management clarified that while a PMS license is held, there is **zero active AUM** following a business sale in 2016. ## D. Technology & Innovation * **AI-Driven Infrastructure:** Developed **RetailAir** for automated B2B fulfillment and a B2C AI counseling tool, though full market rollout faces a **six-month delay** pending consumer readiness. * **Long-term Digital Strategy:** Sustained investment in AI platforms aims to disrupt traditional healthcare delivery models. ## E. Growth Opportunities * **Institutional & Backup Supply:** Targeting the hospital sector via next-day emergency fulfillment and capturing **5% to 6%** of retailer "backup" purchases during supply chain disruptions. * **Logistics Scaling:** Future roadmap includes a disciplined expansion of **10,000 micro-warehouses** to facilitate rapid fulfillment in Tier-2 and Tier-3 towns. --- # 4. Capacity & Infrastructure ## A. Key Figures * **Future Capacity Pipeline:** **1 lakh sq. ft.** Additional space live by **March 31, 2027** * **Revenue Target Support:** **₹6,000 crore** Capacity-enabled scale objective ## B. Manufacturing & Capacity * **Strategic Infrastructure Expansion:** Massive footprint growth driven by AI-led automation and centralized fulfillment to handle surging volumes. * **Regional Hub Strategy:** Leveraging core facilities in West Bengal, Noida, and Assam to penetrate high-growth markets across **10+ states**, including the Northeast and Hindi heartland. * **Logistics Roadmap:** Aggressive build-out of new warehouses in **Udaipur, Lucknow, and Patna**, alongside a capacity doubling at the Noida hub by **September**. ## C. Cost Structure * **Payroll Internalization:** Shifted fulfillment and logistics staff from outsourced contracts to internal payroll, reclassifying "Other Expenses" into "Employee Expenses." * **Margin Neutrality:** Transition is cost-neutral as the elimination of **3% to 4%** outsourcing agency fees offsets the rise in internal administrative and statutory costs. --- # 5. Risks & Financial Factors ## A. Key Figures * Benchmark Returns: **6-7%** (Govt. bonds/industry standard) ## B. Financial Risks * **Treasury Strategy:** Management employs a measured risk approach in treasury operations to generate alpha over standard benchmarks while maintaining a specific tax-efficient corporate structure. * **Portfolio Composition:** The investment book is exposed to **unquoted shares, Alternative Investment Funds (AIFs), and private credit**, which introduces specific liquidity and capital protection considerations. ## C. Capital Protection * **Shareholder Value Preservation:** To prevent holding company "deadlock," management is evaluating strategic pivots including potential **delisting, mergers, or new partnerships** to ensure a profitable exit. --- # 6. Guidance & Outlook ## A. Key Figures * **Infrastructure:** **₹234 Cr** Planned Capex · **8 Lakh+ sq. ft.** Total Projected Capacity ## B. Revenue Targets * **Long-term Growth Roadmap:** Management aims for a massive top-line scale by 2030, bifurcated between B2B (Retailer Shakti) and B2C (Sasta Sundar App) in a **2:1 ratio**. * **Near-term Milestones:** Anticipating a record-breaking Q1 FY27, surpassing previous highs set during the Flipkart partnership, while targeting a **5%-7% market share** in Northern and Northeast regions within three years. * **Mix Optimization:** Strategy includes a aggressive pivot in product mix, aiming to quintuple the revenue share of **non-medicine sales** to **10%** within one year. ## C. Profitability Projections * **J-Curve Profitability:** Expecting a "building phase" characterized by negative profits and low ROE through **FY27 and FY28**, before hitting a significant inflection point in **FY29**. * **Efficiency at Scale:** Long-term guidance suggests a high-velocity return profile, targeting a **40% ROE** once the ₹6,000 Cr revenue scale is achieved. * **Operational Outlook:** FY27 is positioned to be a landmark year for the company, driven by record revenues and margin expansion within the **Jito** segment. ## D. Infrastructure Timeline * **Network Expansion:** Massive capacity ramp-up underway with **5.52 lakh sq. ft.** of new space across Udaipur, Lucknow, Patna, and Guwahati to support the 2030 revenue vision. * **Operational Readiness:** New warehousing facilities are slated to go live within the **current financial year**, providing the necessary fulfillment backbone for the projected scale-up.